×

Targeted/immunomodulatory fusion proteins

  • US 8,815,247 B2
  • Filed: 03/13/2013
  • Issued: 08/26/2014
  • Est. Priority Date: 04/30/2012
  • Status: Active Grant
First Claim
Patent Images

1. A chimeric fusion protein comprising at least one targeting moiety to target a cancer cell and at least one immunomodulating moiety that counteracts immune tolerance, wherein the targeting moiety and the immunomodulating moiety are linked by an amino acid spacer of sufficient length of amino acid residues so that both moieties can successfully bind to their individual target, wherein the immunomodulating moiety is SEQ ID NO:

  • 4, wherein the amino acid spacer is selected from SEQ ID NO;

    3 or SEQ ID NO;

    11; and

    wherein one targeting moiety is an antibody selected from Anti-EGFR1 (heavy chain SEQ ID NO;

    5 and light chain SEQ ID NO;

         6);

    wherein SEQ ID NO;

    4 is attached via the amino acid spacer to the C-terminus of SEQ ID NO 5 or SEQ ID NO;

    6.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×